title: [Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer].
abstract: The study or antitumor effects of dioxadet, cisplatin, melphalan, paclitaxel, mitomycin C, cyclophosphamide and gemcitabine at intraperitoneal (i.p.) and intravenous (i.v.) administration as monochemotherapy and polychemotherapy in a rat model of ascitic ovarian cancer was carried out in 244 female Wistar rats. Ovarian cancer was transplanted i.p. at a number of 1 x 10(7) tumor cells. The drugs were administered once in 48 hours after ovarian cancer transplantation i.p. or i.v. for monotherapy--in maximum tolerated doses, for i.p. polychemotherapy--in half doses from maximum tolerated doses. Antitumor effects of the treatment were estimated in increase in median survival time (MST) compared to control rats who were administered saline i.p. At i.p. administration dioxadet, cisplatin and melphalan increased MST by 79%, 88% and 144%, respectively, while at i.v. administration these drugs didn't affect MST. Mitomycin C and paclitaxel had stronger antitumor action at i.v. administration increasing MST by 152% and 81%, respectively, while at i.p. administration these drugs increased MST by 35 and 45%, respectively. Combinations dioxadet + cisplatin, dioxadet + cyclophosphamide and dioxadet + paclitaxel at i.p. administration increased MST by 305%, 277% and 133%, respectively, and had additive antitumor action compared to mono-effects of these drugs. Gemcitabine and combination dioxadet + gemcitabine at i.p. administration didn't significantly affect survival of rats with ovarian cancer. Intraperitoneal monochemotherapy and polychemotherapy could be more effective in the treatment of peritoneal carcinomatosis from ovarian cancer compared to systemic administration of the drugs.
authors.forename: V G
authors.initials: VG
authors.lastname: Bespalov
authors.forename: E A
authors.initials: EA
authors.lastname: Vyshinskaya
authors.forename: I N
authors.initials: IN
authors.lastname: Vasilieva
authors.forename: M A
authors.initials: MA
authors.lastname: Maidin
authors.forename: A L
authors.initials: AL
authors.lastname: Semenov
authors.forename: A N
authors.initials: AN
authors.lastname: Stukov
authors.forename: G S
authors.initials: GS
authors.lastname: Kireeva
authors.forename: O A
authors.initials: OA
authors.lastname: Belyaeva
authors.forename: O S
authors.initials: OS
authors.lastname: Kopteva
authors.forename: L A
authors.initials: LA
authors.lastname: Krasilnikova
authors.forename: V A
authors.initials: VA
authors.lastname: Alexandrov
authors.forename: A M
authors.initials: AM
authors.lastname: Belyaev
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D020714:Maximum Tolerated Dose; D008558:Melphalan / Q000008:administration & dosage; D016685:Mitomycin / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D051381:Rats; D017208:Rats, Wistar; D014227:Triazines / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D014227:Triazines; D003841:Deoxycytidine; D016685:Mitomycin; C040269:dioxadet; D003520:Cyclophosphamide; D017239:Paclitaxel; D002945:Cisplatin; D008558:Melphalan; D000093542:Gemcitabine